We are live on ! Find out more
EAM

Exome Asset Management Portfolio holdings

AUM $193M
1-Year Est. Return 208.51%
This Fund
S&P 500
This Quarter Est. Return
+14.64%
1 Year Est. Return
+208.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$193M
AUM Growth
-$15.8M
Cap. Flow
-$20.2M
Cap. Flow %
-10.45%
Top 10 Hldgs %
42.42%
Holding
83
New
23
Increased
5
Reduced
24
Closed
27

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$4.1M
2
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$3.95M
3
MAZE
Maze Therapeutics
MAZE
+$3.91M
4
BSX icon
Boston Scientific
BSX
+$3.87M
5
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$3.57M

Top Sells

Rank Stock Value
1
WVE icon
Wave Life Sciences
WVE
+$5.49M
2
AZN icon
AstraZeneca
AZN
+$5.26M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$4.5M
4
IMVT icon
Immunovant
IMVT
+$4.03M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$3.91M

Sector Composition

Rank Sector Weight
1 Healthcare 87.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONC
26
CALL
BeOne Medicines Ltd
ONC
$33.1B
$2.97M 1.54%
+10,000
New +$3.24M
GLUE icon
27
Monte Rosa Therapeutics
GLUE
$2B
$2.95M 1.53%
+179,484
New +$3.43M
ISRG icon
28
Intuitive Surgical
ISRG
$124B
$2.93M 1.52%
6,358
– –
ADAG
29
Adagene
ADAG
$243M
$2.89M 1.49%
736,845
-323,376
-31% -$936K
ARWR icon
30
Arrowhead Research
ARWR
$10.5B
$2.87M 1.48%
45,721
-4,037
-8% -$256K
CBIO
31
Crescent Biopharma
CBIO
$594M
$2.81M 1.46%
+153,191
New +$1.76M
RLAY icon
32
Relay Therapeutics
RLAY
$4.21B
$2.77M 1.43%
+278,302
New +$2.49M
MAZE
33
Maze Therapeutics
MAZE
$1.62B
$2.64M 1.37%
+88,510
New +$3.91M
CTMX icon
34
CytomX Therapeutics
CTMX
$745M
$2.45M 1.27%
521,468
-223,837
-30% -$1.14M
AVTX icon
35
Avalo Therapeutics
AVTX
$989M
$2.38M 1.23%
+159,341
New +$2.49M
ALMS
36
PUT
Alumis Inc
ALMS
$3.83B
$2.31M 1.2%
105,000
+51,800
+97% +$1.29M
GKOS icon
37
Glaukos
GKOS
$8.99B
$2.25M 1.16%
20,874
-10,597
-34% -$1.19M
CRBP icon
38
Corbus Pharmaceuticals
CRBP
$166M
$2.2M 1.14%
234,136
+94,593
+68% +$796K
PEN icon
39
Penumbra
PEN
$12.5B
$2.07M 1.07%
6,300
-2,700
-30% -$914K
SLNO
40
DELISTED
Soleno Therapeutics
SLNO
$2.06M 1.07%
+61,673
New +$2.42M
LQDA icon
41
Liquidia Corp
LQDA
$7.19B
$1.73M 0.89%
45,796
-45,352
-50% -$1.68M
ZBIO
42
Zenas BioPharma
ZBIO
$2.04B
$1.58M 0.82%
+80,730
New +$1.81M
LQDA icon
43
PUT
Liquidia Corp
LQDA
$7.19B
$1.51M 0.78%
+40,000
New +$1.48M
NBP
44
NovaBridge Biosciences American Depositary Shares
NBP
$212M
$1.42M 0.73%
576,960
+77,373
+15% +$259K
CNTA
45
PUT
DELISTED
Centessa Pharmaceuticals
CNTA
$1.38M 0.71%
+34,700
New +$888K
IDYA icon
46
CALL
IDEAYA Biosciences
IDYA
$3.46B
$1.33M 0.69%
+40,000
New +$1.34M
IDYA icon
47
PUT
IDEAYA Biosciences
IDYA
$3.46B
$1.33M 0.69%
+40,000
New +$1.34M
FDMT icon
48
4D Molecular Therapeutics
FDMT
$595M
$1.22M 0.63%
+130,564
New +$1.14M
NXTC icon
49
NextCure
NXTC
$20.8M
$1.22M 0.63%
115,500
-49,500
-30% -$605K
PALI icon
50
Palisade Bio
PALI
$334M
$1.05M 0.54%
600,000
-158,203
-21% -$288K
1
2
3 4

Similar funds

WWC
Waypoint Wealth Counsel Atlanta, Georgia $193M AUM 30.17% 1-Year Est. Return
JHA
Jackson Hill Advisors Houston, Texas $193M AUM 4.94% 1-Year Est. Return
TDWM
Topel & Distasi Wealth Management Berkeley, California $193M AUM 12.07% 1-Year Est. Return
MUAMU
Mitsubishi UFJ Asset Management (UK) London, United Kingdom $193M AUM 37.43% 1-Year Est. Return
DF
Downshift Financial Boulder, Colorado $193M AUM
BW
BostonPremier Wealth Hanover, Massachusetts $194M AUM 20.19% 1-Year Est. Return
SCM
Sandler Capital Management New York $193M AUM 77.14% 1-Year Est. Return
CWRP
Cassady Wealth & Retirement Planning Henderson, Nevada $193M AUM

Exome Asset Management's Q1 2026 Portfolio in Review

As of Q1 2026, Exome Asset Management held 83 positions worth $193M, down 7.6% from $209M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Exome Asset Management withdrew a net $20.2M in Q1 2026, closing 27 positions and reducing 24 holdings. Its most notable exit was Wave Life Sciences, an estimated $5.49M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 97% a quarter earlier.

Against the trend, Exome Asset Management opened a new position in Insmed worth $4.36M.

  • Exome Asset Management's largest Q1 2026 buy was Insmed: 26,651 shares worth $4.36M.
  • Exome Asset Management added most to UnitedHealth in Q1 2026, an estimated $2.09M increase.
  • Exome Asset Management's biggest Q1 2026 reduction was Praxis Precision Medicines, cutting an estimated $3.91M.
  • Exome Asset Management fully exited Wave Life Sciences in Q1 2026, selling an estimated $5.49M.
  • Exome Asset Management's ten largest holdings make up 42% of its $193M portfolio in Q1 2026.
  • Exome Asset Management opened 23 new positions and closed 27 in Q1 2026.
  • Exome Asset Management's portfolio value fell 7.6% quarter-over-quarter to $193M.

Based on Exome Asset Management's 13F filing for Q1 2026, filed 15 May 2026.